Illumina (NASDAQ:ILMN) Price Target Raised to $230.00 at JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its target price raised by investment analysts at JPMorgan Chase & Co. from $220.00 to $230.00 in a report released on Friday,Benzinga reports. The firm currently has an “overweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 14.35% from the stock’s previous close.

Several other research firms have also recently weighed in on ILMN. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Citigroup raised their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $175.47.

Illumina Trading Down 1.9%

Shares of ILMN stock traded down $3.94 on Friday, hitting $201.15. The stock had a trading volume of 2,462,914 shares, compared to its average volume of 1,891,493. Illumina has a twelve month low of $88.00 and a twelve month high of $205.47. The firm has a market cap of $30.43 billion, a P/E ratio of 36.62, a PEG ratio of 2.88 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a fifty day moving average price of $175.49 and a two-hundred day moving average price of $146.83.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the business posted $1.19 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock valued at $155,710,908 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Illumina

A number of large investors have recently modified their holdings of ILMN. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $25,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in Illumina in the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Activest Wealth Management raised its stake in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported second-quarter revenue of $1.16 billion, up roughly 9.5% year over year and ahead of the $1.13 billion consensus estimate. Non-GAAP earnings of $1.31 per share also exceeded expectations of $1.23. Illumina Q2 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 outlook to approximately $4.60 billion-$4.64 billion in revenue and $5.30-$5.40 in non-GAAP EPS, above the current analyst EPS consensus. Clinical demand and continued NovaSeq X placements were key growth drivers. Illumina Q2 Earnings Call Highlights
• Positive Sentiment: Analysts raised their targets following the results: Stifel Nicolaus increased its target from $155 to $225 and maintained a “buy” rating, while TD Cowen raised its target from $192 to $210 but kept a “hold” rating. Benzinga analyst price-target updates
• Positive Sentiment: Eli Lilly joined Illumina’s Billion Cell Atlas alliance, potentially strengthening Illumina’s role in large-scale genomic research and AI-enabled drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
• Neutral Sentiment: Recent institutional positioning was mixed, with several large investors adding shares while others reduced holdings. Government awards and contracts provided an additional, but relatively modest, source of demand.
• Negative Sentiment: Greater China revenue fell 12%, and management left full-year non-GAAP operating-margin guidance unchanged at 23.4%-23.6%. Investors also expect NovaSeq X placement growth to moderate in the second half, contributing to a “sell-the-news” reaction after the earnings beat.
• Negative Sentiment: Reported insider activity was heavily weighted toward selling over the past six months, including substantial sales by Keith Meister. While insider transactions may reflect personal liquidity needs, the pattern can add to investor caution.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.